Analysis of Particulate Matter in Liquid-Finished Dosage Forms

Area of Science:

• Pharmaceutical Manufacturing
• Analytical Chemistry
• Quality Control

Background:

• Particulate matter is a recognized challenge in parenteral formulations, with regulatory bodies requiring "practically free" solutions.
• Pharmaceutical manufacturers must maintain control over processes to minimize particle contamination.
• Existing methods like visual inspection and Acceptable Quality Limits (AQLs) are used to monitor particle occurrence.

Purpose of the Study:

• To present a detailed particle characterization approach for parenteral products.
• To demonstrate the implementation of a particle life-cycle program to control and reduce particulate matter.
• To showcase the benefits of enhanced process understanding and root cause analysis in pharmaceutical manufacturing.

Main Methods:

• Establishment of a dedicated particle laboratory operating under clean room conditions.
• Implementation of a particle life-cycle program focused on characterization and source identification.
• Application of Quality by Design (QbD) principles in particle analysis and control strategies.

Main Results:

• Significant improvement in product and process understanding.
• Reduction in reject rates, AQL failures, and batch rejections.
• Increased availability of pharmaceutical products for patients.

Conclusions:

• A comprehensive particle characterization program is essential for controlling particulate matter in parenteral products.
• Implementing a particle life-cycle approach enhances process control and product quality.
• Improved analytical capabilities lead to better root cause analysis and reduced manufacturing defects.